Spots Global Cancer Trial Database for radioligand therapy
Every month we try and update this database with for radioligand therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT06377683 | Metastatic Cast... | 177Lu-Dansyl-PS... | 21 Years - | The First Affiliated Hospital of Xiamen University | |
| Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics | NCT06260410 | Prostate Cancer... | Blood draw for ... | 18 Years - | Erasmus Medical Center | |
| Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer | NCT05410821 | Refractory Thyr... Refractory Thyr... Refractory Thyr... Refractory Thyr... | 177Lu-DOTA-EB-F... 177Lu-DOTA-EB-F... 177Lu-DOTA-EB-F... | 18 Years - | The First Affiliated Hospital of Xiamen University | |
| [Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer | NCT06229366 | Prostate Cancer Metastatic Cast... Biochemically R... | [Ac-225]-PSMA-6... [Ac-225]-PSMA-6... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) | NCT05432193 | Pancreatic Duct... Colorectal Canc... Esophageal Canc... Melanoma (Skin) Soft Tissue Sar... Head and Neck S... Cholangiocarcin... | [Ga-68]-PNT6555 [Lu-177]-PNT655... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment | NCT04647526 | Metastatic Cast... | [Lu-177]-PNT200... Abiraterone Enzalutamide | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | NCT06147037 | Advanced Solid ... Metastatic Colo... Head and Neck S... Non-small Cell ... Pancreatic Duct... | FPI-2053 [111In]-FPI-210... [225Ac]-FPI-206... | 18 Years - | Fusion Pharmaceuticals Inc. | |
| A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | NCT05977322 | Pancreatic Duct... Gastroesophagea... Glioblastoma Mu... | 68Ga-FF58 177Lu-FF58 | 18 Years - | Novartis | |
| [Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer | NCT06229366 | Prostate Cancer Metastatic Cast... Biochemically R... | [Ac-225]-PSMA-6... [Ac-225]-PSMA-6... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study) | NCT04833517 | Prostate Cancer... Castration Resi... Advanced Prosta... | 18 Years - | Universität des Saarlandes | ||
| A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. | NCT05109728 | Glioblastoma | [177Lu]Lu-DOTA-... [68Ga]Ga-DOTA-T... Temozolomide Radiotherapy | 18 Years - | Novartis | |
| Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT06377683 | Metastatic Cast... | 177Lu-Dansyl-PS... | 21 Years - | The First Affiliated Hospital of Xiamen University | |
| Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors | NCT05963386 | Refractory Soli... | 177Lu-DOTA-EB-F... | 18 Years - 90 Years | The First Affiliated Hospital of Xiamen University | |
| Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer | NCT04085991 | Prostate Cancer Prostate Adenoc... Prostatic Neopl... Metastatic Pros... Metastatic Pros... Metastatic Pros... | 131I-PSMA-1095 ... | 18 Years - | Sir Mortimer B. Davis - Jewish General Hospital | |
| 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer | NCT05204927 | Metastasis From... | 177Lu-PSMA-I&T Abiraterone wit... | 18 Years - | Curium US LLC | |
| A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | NCT05977322 | Pancreatic Duct... Gastroesophagea... Glioblastoma Mu... | 68Ga-FF58 177Lu-FF58 | 18 Years - | Novartis | |
| FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) | NCT05432193 | Pancreatic Duct... Colorectal Canc... Esophageal Canc... Melanoma (Skin) Soft Tissue Sar... Head and Neck S... Cholangiocarcin... | [Ga-68]-PNT6555 [Lu-177]-PNT655... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer | NCT04663997 | Prostate Cancer | 177Lu-PSMA-617 Docetaxel | 18 Years - | Canadian Cancer Trials Group | |
| An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC | NCT04720157 | Prostatic Neopl... | 177Lu-PSMA-617 68Ga-PSMA-11 ARDT ADT | 18 Years - | Novartis | |
| Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors | NCT05963386 | Refractory Soli... | 177Lu-DOTA-EB-F... | 18 Years - 90 Years | The First Affiliated Hospital of Xiamen University | |
| 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer | NCT04663997 | Prostate Cancer | 177Lu-PSMA-617 Docetaxel | 18 Years - | Canadian Cancer Trials Group | |
| An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC | NCT04720157 | Prostatic Neopl... | 177Lu-PSMA-617 68Ga-PSMA-11 ARDT ADT | 18 Years - | Novartis | |
| Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression | NCT06375564 | Refractory Soli... | 177Lu-AB-3PRGD2... | 18 Years - 90 Years | The First Affiliated Hospital of Xiamen University | |
| A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. | NCT05109728 | Glioblastoma | [177Lu]Lu-DOTA-... [68Ga]Ga-DOTA-T... Temozolomide Radiotherapy | 18 Years - | Novartis | |
| FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NCT06402331 | Metastatic Cast... | FPI-2265 | 18 Years - | Fusion Pharmaceuticals Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
